- Laverdia is the first FDA-approved oral, at-home treatment for canine lymphoma.
- The approval converts the drug’s 2021 conditional approval to full FDA approval.
- The therapy is available to U.S. veterinarians through Dechra Veterinary Products.
- Anivive said the approval also validates its AI-driven drug repurposing and clinical development platform.
Anivive Lifesciences announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has granted full approval for Laverdia (verdinexor tablets) for the treatment of canine lymphoma.
The approval makes Laverdia the first FDA-approved oral therapy designed to allow dogs with lymphoma to be treated at home. The decision also converts the product’s 2021 conditional approval to full approval after the company completed the required technical efficacy studies.
Laverdia is an XPO1 inhibitor that targets proteins involved in cancer cell survival. According to Anivive, clinical studies demonstrated the treatment had a favorable safety profile while providing veterinarians with an additional option for managing one of the most common canine cancers.
The product is marketed in the United States through Dechra Veterinary Products under a licensing agreement established in 2022. Dechra plans to launch educational resources and support programs for veterinary teams and pet owners later this summer.
Anivive also said the approval represents the first product developed through its artificial intelligence-enabled drug repurposing platform to achieve FDA approval. The company is pursuing regulatory approvals for Laverdia in Australia, Brazil, Canada, Europe, Japan, and the United Kingdom while continuing to investigate verdinexor for additional veterinary oncology applications.
Information sourced from the company’s press release.
